ISSN: 0034-8376
eISSN: 2564-8896






Mantle cell lymphoma may have a different clinical course in Mexican Mestizos: Real-world data from a single center



Alejandra C. Córdova-Ramírez, Centro de Hematología y Medicina Interna de Puebla, Pue.; Universidad Popular Autónoma del Estado de Puebla, Pue.; Mexico
Luisa F. Sánchez-Valledor, Centro de Hematología y Medicina Interna de Puebla, Pue.; Universidad de las Américas Puebla, Pue.; Mexico
Gerardo Colón-Otero, Mayo Clinic, Jacksonville FL, USA
Montserrat Rivera-Alvarez, Centro de Hematología y Medicina Interna de Puebla, Pue.; Universidad Popular Autónoma del Estado de Puebla, Pue.; Mexico
Gilberto D. Elías-de-la-Cruz, Centro de Hematología y Medicina Interna de Puebla, Pue.; Universidad Popular Autónoma del Estado de Puebla, Pue.; Mexico
Iván Murrieta-Alvarez, Centro de Hematología y Medicina Interna de Puebla, Pue.; Universidad Popular Autónoma del Estado de Puebla, Pue.; Mexico
Yahveth Cantero-Fortiz, Centro de Hematología y Medicina Interna de Puebla; Universidad de las Américas Puebla, Puebla, Mexico
Andrés León-Peña, Centro de Hematología y Medicina Interna de Puebla, Clínica Ruiz, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
Juan C. Olivares-Gazca, Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, Pue.; Universidad Popular Autónoma del Estado de Puebla, Puebla , Pue; Mexico
Guillermo J. Ruiz-Delgado, Centro de Hematología y Medicina Interna, Clínica RUIZ; Universidad Popular Autónoma del Estado de Puebla; Laboratorios Clínicos de Puebla, Clínica RUIZ, Puebla, Pue., Mexico
Guillermo J. Ruiz-Argüelles, Centro de Hematología y Medicina Interna, Clínica RUIZ; Universidad Popular Autónoma del Estado de Puebla; Universidad de las Américas Puebla; Laboratorios Clínicos de Puebla, Clínica RUIZ, Puebla, Pue., Mexico


Background: The biology of some hematological diseases varies among different populations. No previous studies have evaluated the clinical behavior of mantle cell lymphoma (MCL) in México. Objective and Methods: This is a retrospective review of MCL cases seen in Mexico from January 2003 to June 2020. A total of 12 cases were identified. Results: There were nine males and three females; median age was 56 years. Eight patients had a high MCL international prognostic index score, one was intermediate, and three were low. Five patients had circulating malignant monoclonal cells. Initial treatment included rituximab, cyclophosphamide, daunorubicin, vincristine, and prednisone (R-CHOP) and CHOP. Subsequent treatment included hematopoietic stem cell transplantation in five patients; two were given maintenance therapy. Splenectomy was done in four patients. Median overall survival (OS) for all the patients has not been reached and exceeds 162 mos: OS at 162 mos was 56%. Achieving a complete remission (CR) after the first treatment was a significant prognostic factor, with a median OS exceeding 141 mos in patients achieving CR, and 16 mos among those not achieving CR (p = 0.0006). Conclusion: Some of MCL patients in Mexico have an indolent clinical course, particularly patients who achieve a CR to initial treatment and who undergo splenectomy.



Keywords: Mantle cell. Non-Hodgkin. Lymphoma. Treatment. Prognosis.